Back to 
NATIXIS
NATIXIS
SYRE
2 quarters
Position history for NATIXIS's holdings in SPYRE THERAPEUTICS INC
No. Natixis exited its SYRE (Spyre Therapeutics) position in Q3 2025. Its Q2 2025 13F listed 20,040 shares worth $354,908. Natixis first reported SYRE in Q2 2025 and held it in 1 quarterly 13F filing.
Final Value
$0
Final Shares
0
Total Value Change
-$354,908
Total Shares Change
-20,040
Quarter-by-Quarter History